Moreover, it has been reported that natural compounds and drugs used for the treatment of NAFLD targeting the PPARα signaling pathway are dependent on SIRT1 activity [87,88,89]. Here, SIRT1 is linked to metabolic dysfunction-associated steatotic liver disease.